BACKGROUND: As of 2013, more than 550,000 people are living with non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: We undertook a large Surveillance Epidemiology and End Results (SEER) based analysis to describe outcome disparities in different subgroups of aggressive T-cell and B-cell NHL patients, with a focus on various ethnicities. RESULTS: The final analysis included 7662 patients with T-cell and 84,910 with B-cell NHL. Survival analysis revealed that male sex and increasing age were independent predictors of worse overall survival (OS; P < .001). For aggressive T-cell NHL, there was no significant improvement in median OS between 1973 and 2011 (P = .081), and ethnic minorities (Asians, Hispanics, and African Americans) had significantly worse OS than whites (P < .001). There were similar trends for age, sex, and race for diffuse large B-cell NHL, but a significant improvement in median OS was seen over time (P < .001). CONCLUSION: These results are the first to elicit outcomes in a broad classification of ethnic minorities and underscore the urgency for development of novel therapeutics, especially in T-cell NHL. In addition, in-depth studies of disease biology and health care utilization are required for better triage of health care resources, especially for ethnic minorities.
BACKGROUND: As of 2013, more than 550,000 people are living with non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: We undertook a large Surveillance Epidemiology and End Results (SEER) based analysis to describe outcome disparities in different subgroups of aggressive T-cell and B-cell NHL patients, with a focus on various ethnicities. RESULTS: The final analysis included 7662 patients with T-cell and 84,910 with B-cell NHL. Survival analysis revealed that male sex and increasing age were independent predictors of worse overall survival (OS; P < .001). For aggressive T-cell NHL, there was no significant improvement in median OS between 1973 and 2011 (P = .081), and ethnic minorities (Asians, Hispanics, and African Americans) had significantly worse OS than whites (P < .001). There were similar trends for age, sex, and race for diffuse large B-cell NHL, but a significant improvement in median OS was seen over time (P < .001). CONCLUSION: These results are the first to elicit outcomes in a broad classification of ethnic minorities and underscore the urgency for development of novel therapeutics, especially in T-cell NHL. In addition, in-depth studies of disease biology and health care utilization are required for better triage of health care resources, especially for ethnic minorities.
Authors: Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew Journal: Adv Cancer Res Date: 2019-04-23 Impact factor: 6.242
Authors: Catalina Amador; Timothy C Greiner; Tayla B Heavican; Lynette M Smith; Karen Tatiana Galvis; Waseem Lone; Alyssa Bouska; Francesco D'Amore; Martin Bjerregaard Pedersen; Stefano Pileri; Claudio Agostinelli; Andrew L Feldman; Andreas Rosenwald; German Ott; Anja Mottok; Kerry J Savage; Laurence de Leval; Philippe Gaulard; Soon Thye Lim; Choon Kiat Ong; Sarah L Ondrejka; Joo Song; Elias Campo; Elaine S Jaffe; Louis M Staudt; Lisa M Rimsza; Julie Vose; Dennis D Weisenburger; Wing C Chan; Javeed Iqbal Journal: Blood Date: 2019-12-12 Impact factor: 25.476
Authors: Renata Abrahão; Raul C Ribeiro; Daphne Y Lichtensztajn; Aaron S Rosenberg; Theresa H M Keegan Journal: Pediatr Blood Cancer Date: 2018-12-04 Impact factor: 3.838
Authors: Harry Comber; Marianna De Camargo Cancela; Trutz Haase; Howard Johnson; Linda Sharp; Jonathan Pratschke Journal: PLoS One Date: 2016-12-19 Impact factor: 3.240